Kiniksa Pharmaceuticals International, plc

What they do

Kiniksa develops and commercializes therapies for diseases with unmet need, concentrating on cardiovascular indications. Its lead commercial product, ARCALYST, is an IL-1α and IL-1β cytokine trap licensed from Regeneron in 2017, which Kiniksa sells and distributes in the U.S. while splitting profits evenly with Regeneron. The company also advances an independent pipeline of IL-1R1 antibodies (KPL-387, KPL-1161) and holds a license to abiprubart, for which it is exploring strategic alternatives after discontinuing development in Sjögren's Disease.

Revenue drivers

• ARCALYST U.S. net product revenue — ARCALYST is sold in the U.S. through a select network of specialty pharmacies; it is approved for recurrent pericarditis, CAPS and DIRA, and is the company's sole source of product revenue, generating $243.6 million in Q2 2026 alone.
• Profit split with Regeneron — Kiniksa is responsible for U.S. sales and distribution but evenly splits profits on ARCALYST sales and third-party proceeds with Regeneron, so reported net product revenue overstates the economics retained.
• Huadong out-license (ARCALYST, China territory) — In 2022 Kiniksa granted Hangzhou Zhongmei Huadong Pharmaceutical exclusive rights to develop and commercialize ARCALYST in the Huadong Territory, a potential source of milestone and royalty proceeds.

Recent performance

Q2 2026 ARCALYST net product revenue was $243.6 million, representing approximately 55% year-over-year growth. As of the end of Q2 2026, about 21% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment, and more than 5,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis since launch. Average total duration of ARCALYST therapy in recurrent pericarditis was approximately three years, in line with the median disease duration. The company raised its full-year 2026 ARCALYST net sales guidance to $980–$995 million.

Strategy

Kiniksa is maximizing ARCALYST in recurrent pericarditis through prescriber breadth and patient persistence while advancing KPL-387, an independent IL-1R1 antibody, into Phase 3. In June 2026 the FDA approved Samsung Biologics as the replacement contract development and manufacturing organization for ARCALYST drug substance, following a Regeneron-initiated technology transfer. KPL-387's pivotal Phase 3 trial, PASTORALE, is enrolling and dosing patients, with commercialization expected in 2028 or 2029. KPL-1161, an Fc-modified version of KPL-387 targeting quarterly subcutaneous dosing, is in preclinical work with a Phase 1 trial expected by the end of 2026. The company is also running a supplemental Phase 2 transition-to-monotherapy study and exploring strategic alternatives for abiprubart.

Risks

• Single-product concentration — All product revenue comes from ARCALYST, so any manufacturing, payer, or competitive setback for that one drug directly hits total sales.
• Third-party manufacturing dependency — Kiniksa relies on contract manufacturers, and the transition of ARCALYST drug substance production to Samsung could cause supply delays or quality issues.
• Profit split limits economics — Because Kiniksa evenly splits ARCALYST profits and third-party proceeds with Regeneron, revenue growth does not translate one-for-one into retained earnings.
• Clinical and regulatory risk for pipeline — KPL-387, KPL-1161 and abiprubart remain investigational; PASTORALE or the KPL-1161 Phase 1 could fail to replicate earlier Phase 2 results or face regulatory delays.

Outlook

Management expects full-year 2026 ARCALYST net product revenue of $980–$995 million, reflecting continued growth in new and repeat prescribers. The pivotal Phase 3 PASTORALE trial of KPL-387 is now enrolling and dosing, with commercialization targeted for 2028 or 2029, and KPL-1161 Phase 1 is expected by the end of 2026. The company also continues its supplemental Phase 2 transition-to-monotherapy study for KPL-387.